It has been suggested that ACE2-mediated inhibition of the AT1R pathway, which is beneficial in the treatment of hypertension, may also increase the susceptibility to pulmonary and cardiovascular disease in patients with COVID-19 [17]. This evidence concerns the gene AGTR1 and cardiovascular disorder.